Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI

Whole-body diffusion weighted imaging (WB-DWI) has proven value to detect multiple myeloma (MM) lesions. However, the large volume of imaging data and the presence of numerous lesions makes the reading process...
Source: Cancer Imaging - Category: Radiology Authors: Tags: Research article Source Type: research

Related Links:

çoise Kraeber-Bodere Multiple myeloma (MM) is always preceded by an initial monoclonal gammopathy of undetermined significance (MGUS) that then develops into asymptomatic or smoldering multiple myeloma (SMM), which constitutes an intermediate clinical stage between MGUS and MM. According to a recent study, risk factors for faster MGUS to MM progression include an M protein of 1.5 g/dL or more and an abnormal free light chain ratio in patients with non-IgM MGUS. Therefore, the International Myeloma Working Group (IMWG) decided to recommend whole-body computed tomography (WBCT) for patients with high-risk MGUS in ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Blood Cancer Journal, Published online: 17 February 2020; doi:10.1038/s41408-020-0284-7Dissecting racial disparities in multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Blood Cancer Journal, Published online: 17 February 2020; doi:10.1038/s41408-020-0285-6Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
Bargou Andreas Rosenwald Thorsten Stühmer Ellen Leich Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRASp.G12C entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, incl...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Giavaresi Alessandro Osteolytic bone disease is the major complication associated with the progression of multiple myeloma (MM). Recently, extracellular vesicles (EVs) have emerged as mediators of MM-associated bone disease by inhibiting the osteogenic differentiation of human mesenchymal stem cells (hMSCs). Here, we investigated a correlation between the EV-mediated osteogenic inhibition and MM vesicle content, focusing on miRNAs. By the use of a MicroRNA Card, we identified a pool of miRNAs, highly expressed in EVs, from MM cell line (MM1.S EVs), expression of which was confirmed in EVs from bone marrow (BM) p...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionOur results demonstrate that Egyptian children diagnosed with JMML have high frequency of NRAS/KRAS mutations and lower frequency of PTPN11 mutations as compared to previous studies. The concept of mutually exclusive RAS pathway mutations was clearly observed in our patients. All cancer centers in our region should start implementing molecular diagnostics methods before confirming the diagnosis of JMML and before offering HSCT.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Bone is one of the most common sites of metastases, particularly for breast, lung, prostate cancer, and multiple myeloma [1]. The most typical anatomical regions of bone metastases are the spine, the proximal femur, and the humerus [2]. Particularly for proximal femur lesions, 50% occur in the femoral neck, 30% occur in the subtrochanteric region, and 20% occur in the intertrochanteric region [3]. While current advances in oncology have improved the mean overall survival of patients with metastatic musculoskeletal disease, bone metastases cause significant morbidity, including pain, limitations in daily activities, and pat...
Source: Injury - Category: Orthopaedics Authors: Source Type: research
Juvenile Myelomonocytic Leukemia (JMML) is a rare hematological malignancy. Developing countries are lagging behind in their facilities in molecular diagnostics. The bone marrow for 41 Egyptian children treated as JMML were retrospectively studied for RAS mutations. Mutations were detected in 80% of patients. Cancer centers in our region should start implementing molecular diagnostics before confirming the diagnosis of JMML.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Sara Palchetti Angela Santoni Cinzia Fionda Bone marrow stromal cells (BMSCs) strongly contribute to multiple myeloma (MM) progression, promoting the survival and growth of malignant plasma cells (PCs). However, the possible impact of these cells on the immune-mediated recognition of MM cells remains largely unknown. DNAM-1 activating receptor plays a prominent role in NK cell anti-MM response engaging the ligands poliovirus receptor (PVR) and nectin-2 on malignant PCs. Here, we analysed the role of MM patient-derived BMSCs in the regulation of PVR expression. We found that BMSCs enhance PVR surface expression on ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Blood Cancer Journal, Published online: 13 February 2020; doi:10.1038/s41408-020-0273-xDevelopments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
Source: Blood Cancer Journal - Category: Hematology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Myeloma | Radiology